Subscribe to RSS
DOI: 10.1055/s-0030-1255419
© Georg Thieme Verlag Stuttgart · New York
Therapie des Typ-2-Diabetes – Zielwerterreichung unter Vermeidung von Nebenwirkungen
Therapy of Type 2 Diabetes – How to Arrive at Target Values Without Side EffectsPublication History
Publication Date:
02 June 2010 (online)

In diesem kurzen Übersichtsartikel soll auf die Bedeutung der antihyperglykämischen Therapie beim Typ-2-Diabetes eingegangen werden. Insbesondere stehen dabei die Ergebnisse der großen Diabetes-Endpunktstudien der letzten Jahre sowie die neue evidenzbasierte Leitlinie der Deutschen Diabetes-Gesellschaft im Fokus, die eine sichere Therapiezielerreichung unter Vermeidung von Hypoglykämien sowie einer ausgeprägten Gewichtszunahme anstreben.
This brief review stresses the significance of anti-hyperglycaemic therapy in cases of type 2 diabetes. Focus is especially on the results of the large-scale Diabetes Final Stage Studies conducted during the past few years and on the new evidence-based guideline compiled by the German Diabetes Association. These efforts have been especially directed at a safe therapy target while avoiding hypoglycaemias and any pronounced increase in body weight.
Key words
Type 2 diabetes - how to arrive at the therapy target - avoidance of hypoglycaemias - evidence-based guidelines by the German Diabetes Association
Literatur
- 1 Gaede P, Andersen HL, Parving HH, Pedersen O.. Effect of a Multifactorial intervention on Mortality in Type Diabetes. N Engl J Med. 2008; 358 580-591
- 2 Duckworth W, Abraira C, Moritz T et al.. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360 129-139
- 3 The Action to Control Cardiovascular Risk in Diabetes Study Group. . Effect of Intensive Glucose Lowering in Type 2 Diabetes. N Eng J Med. 2008; 358 2545-2559
- 4 The ADVANCE Collaborative Group. . Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Eng J Med. 2008; 358 2560-2572
- 5 Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA.. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359 1577-1589
- 6 Matthaei S, Bierwirth R, Fritsche A et al.. Medikamentöse antihyperglykämische Therapie des Diabetes mellitus Typ 2 – Update der evidenzbasierten Leitlinie der Deutschen Diabetes-Gesellschaft. Diabetologie. 2009; 4 32-64
- 7 Holman RR, Farmer AJ, Davies MJ et al.. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009; 361 1736-1747
- 8 Horvath K, Jeitler K, Berghold A et al.. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus (Review). Cochrane Database of systematic Review. 2 CD 005613 2007;
- 9 Bolen S, Feldman L, Vassy J et al.. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Int Med. 2007; 147 386-399
- 10 Leese GP, Wang J, Broomhall J et al.. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population based-study of health service resource use. Diabetes Care. 2003; 26 1176-1180
- 11 UK Hypoglycemia Study Group. . Risk of hypoglycemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007; 50 1140-1147
- 12 UK Prospective Diabetes Study (UKPDS) Group. . Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type-2 diabetes. (UKPDS 33). Lancet. 1998; 352 837-853
- 13 UKPDS Group. . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352 854-865
- 14 Del Prato S, Felton AM, Munro N et al.. Improving glucose management: ten steps to get more patients with type diabetes to glycaemic goal. Int J Clin Pract. 2005; 59 1345-1355
- 15 Del Prato S.. Megatrials in type 2 diabetes. From excitement to frustration?. Diabetologia. 2009; 52 1219-1226
Korrespondenz
Prof. Dr. med. Stephan Matthaei
Diabetes-Zentrum Quakenbrück am Christlichen Krankenhaus
Danziger Str. 10
49610 Quakenbrück
Email: S.Matthaei@ckq-gmbh.de